Avastin plus chemo better without Erbitux
CHICAGO (Reuters) - Colon cancer patients treated with Genentech Inc's Avastin and chemotherapy lived longer without their disease getting worse than those who were also treated with ImClone Systems Inc's Erbitux, according to a study presented on Saturday.
<p><img src="http://feeds.reuters.com/~a/reuters/healthNews?i=Wq5Sm3" border="0"></img> (http://feeds.reuters.com/~a/reuters/healthNews?a=Wq5Sm3)</p><div class="feedflare">
<img src="http://feeds.reuters.com/~f/reuters/healthNews?i=BVUsVH" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=BVUsVH) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=dknw2h" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=dknw2h) <img src="http://feeds.reuters.com/~f/reuters/healthNews?i=DtiKih" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=DtiKih)
</div><img src="http://feeds.reuters.com/~r/reuters/healthNews/~4/301873698" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/301873698/idUSN3044597720080531